Experimental compound targets circadian clock machinery in cells to fight glioblastoma

Novel Compound Targets Cellular Circadian Clock to Combat Glioblastoma

A groundbreaking new compound named SHP1705 is generating excitement in the fight against glioblastoma, the most aggressive and lethal brain tumor diagnosed in adults today. Building on years of research into circadian biology, this novel agent specifically targets circadian clock proteins that glioblastoma stem cells exploit to fuel their relentless growth and survival. Unlike previous therapeutic avenues, SHP1705 offers a precision strategy by…

Experimental compound targets circadian clock machinery in cells to fight glioblastoma

A series of preclinical studies show that a new compound, SHP1705, targets circadian clock proteins hijacked by glioblastoma stem cells, impairing the cancer cells' ability to survive and grow. SHP1705 is also the first clock-targeting compound to complete a phase 1 clinical trial, where it was found to be safe and well-tolerated in humans. A summary of the research is published in the journal Neuro-Oncology.